Amid a backdrop of heightened political uncertainty and fluctuating bond yields in France, investors are closely monitoring the upcoming elections and their potential impact on the market. In such a climate, growth companies with high insider ownership like MedinCell can offer an appealing stability, as significant insider stakes often align management’s interests with those of shareholders, potentially leading to prudent long-term decision-making in turbulent times. Top 10 Growth Companies With High Insider Ownership In France Name Insider Ownership Earnings Growth VusionGroup (ENXTPA:VU) 13.5% 25.2% Groupe OKwind Société anonyme (ENXTPA:ALOKW) 24.8% 30.8% Adocia (ENXTPA:ADOC) 12.1% 59.8% Icape Holding (ENXTPA:ALICA) 30.2% 26.1% Arcure (ENXTPA:ALCUR) 21.4% 42.4% La Française de l'Energie (ENXTPA:FDE) 20.1% 31.9% S.M.A.I.O (ENXTPA:ALSMA) 17.3% 35.2% Munic (ENXTPA:ALMUN) 29.4% 150% WALLIX GROUP (ENXTPA:ALLIX) 19.8% 101.6% MedinCell (ENXTPA:MEDCL) 16.4% 74.9% Click here to see the full list of 22 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. MedinCell Simply Wall St Growth Rating: ★★★★★☆ Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €410.34 million. Operations: The company generates its revenues primarily from the pharmaceuticals segment, amounting to €11.95 million. Insider Ownership: 16.4% MedinCell, a French biotech firm, is navigating through significant growth phases with its high insider ownership aligning interests with long-term success. Despite a recent decline in revenue to €11.95 million and a net loss of €25.04 million for the year ended March 2024, MedinCell is expected to become profitable within three years. Its revenue growth forecast at 43.7% annually outpaces the broader French market significantly. However, challenges remain as evidenced by the failure of its Phase 3 trial for F14 (mdc-CWM), although some secondary improvements were noted in patients treated with F14 compared to standard care alone. Dive into the specifics of MedinCell here with our thorough growth forecast report. Upon reviewing our latest valuation report, MedinCell's share price might be too optimistic. ENXTPA:MEDCL Earnings and Revenue Growth as at Jul 2024 OVH Groupe Simply Wall St Growth Rating: ★★★★☆☆ Overview: OVH Groupe S.A. is a global provider of public and private cloud services, shared hosting, and dedicated server solutions with a market capitalization of €1.13 billion. Operations: The company's revenue is segmented into public cloud (€169.01 million), private cloud (€589.61 million), and web cloud (€185.43 million). Insider Ownership: 10.5% OVH Groupe, a French cloud services provider, is poised for significant growth with high insider ownership. Despite its forecasted low return on equity of 1.7% in three years and a revenue growth rate below 20% per year, earnings are expected to surge by 103.69% annually. Recent advancements include the launch of ADV-Gen3 Bare Metal servers, enhancing performance through AMD EPYC processors and upgraded networks, positioning OVHcloud at the forefront of accessible advanced server technology. This innovation aligns with their profitability expectations within the next three years amidst a volatile share price. Take a closer look at OVH Groupe's potential here in our earnings growth report. The valuation report we've compiled suggests that OVH Groupe's current price could be inflated. ENXTPA:OVH Earnings and Revenue Growth as at Jul 2024 VusionGroup Simply Wall St Growth Rating: ★★★★★★ Overview: VusionGroup S.A., operating in Europe, Asia, and North America, specializes in providing digitalization solutions for commerce with a market capitalization of approximately €2.15 billion. Operations: The company generates revenue primarily through the installation and maintenance of electronic shelf labels, contributing €0.80 billion. Insider Ownership: 13.5% VusionGroup S.A., a French company with high insider ownership, demonstrates robust growth potential. In the last year, its earnings surged by 320.8%, with revenue increasing from €620.86 million to €801.96 million and net income growing to €79.77 million from €18.95 million previously. Analysts forecast a substantial 25% annual earnings growth over the next three years, significantly outpacing the broader French market's expectations of 10.9%. Despite this strong performance and positive outlook, it has experienced high share price volatility recently. Navigate through the intricacies of VusionGroup with our comprehensive analyst estimates report here. According our valuation report, there's an indication that VusionGroup's share price might be on the expensive side. ENXTPA:VU Earnings and Revenue Growth as at Jul 2024 Make It Happen Reveal the 22 hidden gems among our Fast Growing Euronext Paris Companies With High Insider Ownership screener with a single click here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ENXTPA:MEDCL ENXTPA:OVH and ENXTPA:VU. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Euronext Paris Showcases MedinCell And Two More Growth Companies With Significant Insider Ownership
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...